UCSF CME: 39th Annual Advances in Heart Disease 2022

UCSF CME: 39th Annual Advances in Heart Disease 2022

95 $

Format : 5 Videos + 28 PDFs

File Size : 4.44 GB

Category:

UCSF CME: 39th Annual Advances in Heart Disease 2022

 

Our 39th annual course will again strive to present topics that highlight new evidence-based medicine findings reported within the last one to two years that impact clinical practice. These will range across a variety of cardiologic subspecialty interests including heart failure, arrhythmias, cardiac surgery, gene therapy, aortic diseases, prevention and artificial intelligence.

Are you a cardiovascular specialist seeking the latest evidence-based findings to impact your clinical practice? Look no further than the 39th annual course presented by the University of California, San Francisco. This course covers a variety of subspecialty interests including heart failure, arrhythmias, cardiac surgery, gene therapy, aortic diseases, prevention, and artificial intelligence. This exceptional program features prestigious academic faculty from North America along with top physicians and teachers from UCSF.

The course focuses on presenting new evidence-based medicine findings reported in the last one to two years to impact clinical practice. This will help ensure that participants are up-to-date with the latest information relevant to their practice. Additionally, the program emphasizes deep empathy in patient interactions, recognizing that the pathophysiology of diseases and treatment options differ among racial and ethnic groups.

Participants who enroll in the course will have access to all recorded sessions, which will be made available for online viewing 30 days post-course. The objective of the course is to provide the best management of coronary heart disease, hypertension, lipid disorders, diabetes, systolic and diastolic heart failure, atrial fibrillation and flutter, STEMI and non-STEMI, thromboembolic disease, and others.

This course is intended for cardiovascular specialists, practicing cardiologists, internists, family physicians, and cardiovascular experts. It provides an excellent opportunity for professionals in the field to gain new insights into the latest evidence-based medicine findings and learn from some of the most renowned physicians.

The content of the course is divided into several topics, which include Frontiers in Cardiology: Genetics, Artificial Intelligence, and Deep Empathy, State-of-the-Art: Cardiovascular Interventions, Advances and Controversies in Electrophysiology, and Managing Heart Failure. Each topic covers the most relevant information regarding the subject.

Speakers share their knowledge, experience and insights in the cardiovascular field, which are of high value to medical practitioners. For example, Dr. John Chorba, a renowned physician, will talk about new gene targeting treatments for cardiometabolic diseases, while Dr. Edward Gerstenfeld will present advances in cardiac imaging for arrhythmia etiology, prognosis, and therapy. Additionally, Dr. Eric Topol will deliver the Elliot Rapaport Keynote Lecture on High Performance with Deep Empathy Medicine.

The program includes a comprehensive outline and a fantastic panel discussion. One of the sessions, Advances and Controversies in Electrophysiology, includes a debate about AFib ablation, where two renowned doctors argue for and against the procedure’s priority in patients with symptomatic AFib.

Overall, the 39th annual course presented by the University of California, San Francisco is an excellent opportunity for any cardiovascular expert looking to stay up-to-date with the latest medical knowledge. The speakers have unparalleled knowledge and experience in their respective fields, and the course covers topics relevant to the practice of healthcare providers in the heart care sector.

Product Details

  • Providing the best management of coronary heart disease, hypertension, lipid disorders, diabetes, systolic and diastolic heart failure, atrial fibrillation and flutter, STEMI and non-STEMI, thromboembolic disease
  • Refining considerations for atrial fibrillation, atrial flutter, and ventricular tachycardia ablation
  • Applying the best considerations of surgical revascularization or percutaneous intervention for management of coronary heart disease
  • Recognizing risk stratification of cardiovascular disease
  • Optimizing the management of ascending thoracic aorta disease
  • Optimizing the management of pulmonary embolism
  • Recognizing the role of cardiac surgery in the management of endocarditis
  • Recognizing the genetic basis of cardiovascular diseases
  • Recognizing the importance of deep empathy in patient interactions
  • Recognizing that pathophysiology of diseases and treatment options differ among racial and ethnic groups
  • Optimizing the management of cardiac amyloidosis
  • Recognizing the connection between the mind and the heart
  • Recognizing the role of air pollution as a risk factor for cardiovascular diseases

Related Products